Dynavax Technologies Corporation – NASDAQ:DVAX
Dynavax Technologies stock price today
$10.44
-2.56
-19.69%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Dynavax Technologies stock price monthly change
+20.93%
month
Dynavax Technologies stock price quarterly change
+20.93%
quarter
Dynavax Technologies stock price yearly change
-8.00%
year
Dynavax Technologies key metrics
Market Cap | 1.68B |
Enterprise value | 1.42B |
P/E | 5.25 |
EV/Sales | 1.97 |
EV/EBITDA | 4.64 |
Price/Sales | 1.89 |
Price/Book | 2.36 |
PEG ratio | 0.01 |
EPS | 0.07 |
Revenue | 236.14M |
EBITDA | 13.09M |
Income | 9.22M |
Revenue Q/Q | 8.23% |
Revenue Y/Y | -63.98% |
Profit margin | 40.57% |
Oper. margin | 39.09% |
Gross margin | 63.73% |
EBIT margin | 39.09% |
EBITDA margin | 5.55% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDynavax Technologies stock price history
Dynavax Technologies stock forecast
Dynavax Technologies financial statements
| Jun 2023 | 60.24M | 3.43M | 5.69% |
|---|---|---|---|
| Sep 2023 | 69.51M | 14.29M | 20.56% |
| Dec 2023 | 55.59M | 219K | 0.39% |
| Mar 2024 | 50.79M | -8.72M | -17.17% |
| Sep 2025 | 94.16M | 14.51M | 15.41% |
|---|---|---|---|
| Oct 2025 | 92.46M | 11.14M | 12.05% |
| Dec 2025 | 75.44M | 2.17M | 2.88% |
| Mar 2026 | 88.25M | 11.08M | 12.56% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 936432000 | 359.22M | 38.36% |
|---|---|---|---|
| Sep 2023 | 972933000 | 368.01M | 37.83% |
| Dec 2023 | 997096000 | 375.02M | 37.61% |
| Mar 2024 | 986565000 | 368.08M | 37.31% |
| Jun 2023 | 28.04M | 24.72M | -294K |
|---|---|---|---|
| Sep 2023 | 31.12M | -106.07M | 2.99M |
| Dec 2023 | 13.76M | -20.24M | 1.77M |
| Mar 2024 | -16.67M | 2.83M | -4.20M |
Dynavax Technologies alternative data
| Aug 2023 | 351 |
|---|---|
| Sep 2023 | 351 |
| Oct 2023 | 351 |
| Nov 2023 | 351 |
| Dec 2023 | 351 |
| Jan 2024 | 351 |
| Feb 2024 | 351 |
| Mar 2024 | 408 |
| Apr 2024 | 408 |
| May 2024 | 408 |
| Jun 2024 | 408 |
| Jul 2024 | 408 |
Dynavax Technologies other data
75.76%
-6.67%
of DVAX is owned by hedge funds
195
-2
100.76M
+4.39M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 0 | 500000 |
| Aug 2023 | 0 | 1586118 |
| Sep 2023 | 0 | 20000 |
| Oct 2023 | 0 | 46770 |
| Nov 2023 | 0 | 40000 |
| Dec 2023 | 0 | 20000 |
| Jan 2024 | 0 | 10500 |
| Mar 2024 | 0 | 20526 |
| May 2024 | 0 | 3615 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | CANO FRANCIS director | Common Stock | 3,615 | $11.93 | $43,127 | ||
Option | CANO FRANCIS director | Common Stock | 7,500 | $5.9 | $44,250 | ||
Option | CANO FRANCIS director | Stock Option (Right to Buy) | 7,500 | $5.9 | $44,250 | ||
Option | BURGESS JUSTIN officer: Chief Ac.. | Common Stock | 2,767 | $9.41 | $26,037 | ||
Option | BURGESS JUSTIN officer: Chief Ac.. | Common Stock | 4,334 | $11.12 | $48,194 | ||
Sale | BURGESS JUSTIN officer: Chief Ac.. | Common Stock | 7,101 | $12.78 | $90,751 | ||
Option | BURGESS JUSTIN officer: Chief Ac.. | Stock Options (Right to Buy) | 4,334 | $11.12 | $48,194 | ||
Sale | BURGESS JUSTIN officer: Chief Ac.. | Common Stock | 13,425 | $12.78 | $171,572 | ||
Option | BURGESS JUSTIN officer: Chief Ac.. | StockOptions (Right to Buy) | 2,767 | $9.41 | $26,037 | ||
Option | BURGESS JUSTIN officer: Chief Ac.. | Common Stock | 6,667 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 22 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
Dynavax Technologies: Still A Solid Pick For 2024
Ardelyx: The Journey Continues
Dynavax Technologies: Stellar Results, But Little Respect
Bavarian Nordic A/S Could Post A Strong Comeback
What About Goldilocks? These Stocks Are In Bottoming Postures
Week In Review: Henlius Signs $196 Million Deal For 2 Oncology Bifunctional Sialidase Candidates
Dynavax: Evolving Endemic Situation Adds To Its Risk
The Alphavaxers: Dynavax And Novavax - A Tale Of Two Cities
Dynavax Technologies: Full Speed Ahead
-
What's the price of Dynavax Technologies stock today?
One share of Dynavax Technologies stock can currently be purchased for approximately $10.44.
-
When is Dynavax Technologies's next earnings date?
Unfortunately, Dynavax Technologies's (DVAX) next earnings date is currently unknown.
-
Does Dynavax Technologies pay dividends?
No, Dynavax Technologies does not pay dividends.
-
How much money does Dynavax Technologies make?
Dynavax Technologies has a market capitalization of 1.68B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 67.86% to 232.28M US dollars.
-
What is Dynavax Technologies's stock symbol?
Dynavax Technologies Corporation is traded on the NASDAQ under the ticker symbol "DVAX".
-
What is Dynavax Technologies's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Dynavax Technologies?
Shares of Dynavax Technologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Dynavax Technologies's key executives?
Dynavax Technologies's management team includes the following people:
- Mr. Ryan Spencer Chief Executive Officer & Director(age: 47, pay: $859,990)
- Mr. David F. Novack Pres & Chief Operating Officer(age: 63, pay: $799,200)
- Dr. Robert Janssen Chief Medical Officer and Senior Vice President of Clinical Devel., Medical & Regulatory Affairs(age: 71, pay: $725,270)
- Mr. Michael S. Ostrach Advisor(age: 73, pay: $721,350)
-
How many employees does Dynavax Technologies have?
As Jul 2024, Dynavax Technologies employs 408 workers.
-
When Dynavax Technologies went public?
Dynavax Technologies Corporation is publicly traded company for more then 21 years since IPO on 19 Feb 2004.
-
What is Dynavax Technologies's official website?
The official website for Dynavax Technologies is dynavax.com.
-
Where are Dynavax Technologies's headquarters?
Dynavax Technologies is headquartered at 2100 Powell Street, EmeryVille, CA.
-
How can i contact Dynavax Technologies?
Dynavax Technologies's mailing address is 2100 Powell Street, EmeryVille, CA and company can be reached via phone at +51 08485100.
Dynavax Technologies company profile:
Dynavax Technologies Corporation
dynavax.comExchange:
NASDAQ
Full time employees:
408
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
2100 Powell Street
EmeryVille, CA 94608
EmeryVille, CA 94608
CIK: 0001029142
ISIN: US2681582019
CUSIP: 268158201
